FDA approves generic in same class as Ozempic for diabetes. Could it ease shortage, price?
The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could ...
There’s still no generic Ozempic, but a lower-priced daily injected GLP-1 is coming
The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...
Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark.
Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...
FDA approves anti-obesity drug as first sleep apnea medication
The US FDA approved Eli Lilly's Zepbound as the first ever medication for obstructive sleep apnea for patients who also have ...
24/7 Wall St9h
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Bye-bye BBLs: How Y2K fashion and Ozempic created a new class divide
PERSPECTIVES: The resurgence of Y2K skin-baring fashion trends coincides with the rise of prescription weight loss drugs like ...
Why are people microdosing Ozempic?
Tiny doses of the weight-loss drug can sidestep its unpleasant side effects, say influencers. But is customising the dose a ...
BioSpace21h
7 Indications for GLP-1s Beyond Weight Loss
Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the ...
East Idaho News23h
FDA says knockoff versions of obesity drug must come off the market
Specialty pharmacies and online companies that have been selling off-brand copies of two blockbuster drugs for obesity and ...
Is Merck the Next Big Weight-Loss Stock?
And that's why Merck could credibly become the next big weight-loss stock. Before you rush to go buy shares of Merck, ...
Insurancenewsnet.com1d
Weight loss drugs changed their lives. Then they lost coverage
Mindy McCormick, 67, read that her insurer would soon stop covering the weight loss drug Wegovy, which she had been taking for more than two years. Nearly 9,000 people across the state had received ...